Results of the OPTIMIZE trial presented at TCT 2013

New study demonstrates potential benefits of shorter-term dual antiplatelet therapy in patients treated with a second generation drug-eluting stent

2013-10-31

(Press-News.org) Contact information: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Results of the OPTIMIZE trial presented at TCT 2013 New study demonstrates potential benefits of shorter-term dual antiplatelet therapy in patients treated with a second generation drug-eluting stent SAN FRANCISCO, CA – OCTOBER 31, 2013 - A new study demonstrates that some patients may not need to receive prolonged anti-clotting therapy after drug-eluting stent (DES) implantation with the Endeavor zotarolimus-eluting stent, and that shortening the duration could reduce bleeding risks and treatment costs. The OPTIMIZE clinical trial findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Current guidelines recommend long-term (12 month) dual antiplatelet therapy (DAPT) after DES implantation, but the clinical benefits of this regimen remain unclear, especially with newer generation DES. The OPTIMIZE trial enrolled 3,120 patients with largely stable coronary artery disease in a prospective, randomized (1:1) multicenter clinical evaluation that compared short-term (3 month) and long-term (12 month) dual antiplatelet therapy. All patients underwent PCI with Endeavor zotarolimus-eluting stents, a second-generation DES.

The primary endpoint was a composite of Net Adverse Clinical and Cerebral Events (NACCE), which included death from any cause, myocardial infarction, stroke or major bleeding at one year follow-up.

After one year, NACCE rates for patients receiving short-term DAPT were similar to those who received the longer, standard DAPT (6.1 percent vs. 5.9 percent respectively), establishing non-inferiority of the shorter-term therapy (non-inferiority p-value = 0.002).

After 90 days, both groups showed comparable rates of NACCE, stent thrombosis and revascularization. Patients in the long-term DAPT group also showed a trend towards increased bleeding events.

"To date, OPTIMIZE is the only DAPT duration study using a single second-generation DES, and these promising findings could help shorten antiplatelet therapy time and reduce related complication risks for patients receiving select drug-eluting stents," said lead investigator Fausto Feres, MD of the Instituto Dante Pazzanese de Cardiologia in São Paulo, Brazil.

"These outcomes may be especially relevant for patients who are at a high risk of bleeding complications following PCI, such as the elderly and patients with a history of hemorrhagic events."

### The OPTIMIZE trial was funded by Medtronic Comercial Ltda in São Paulo, Brazil. Dr. Feres reported consulting fees/honoraria from Biosensors, Eli Lilly, and Medtronic.

About CRF and TCT The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.

ELSE PRESS RELEASES FROM THIS DATE:

Results of the ARCTIC-INTERRUPTION trial presented at TCT 2013

2013-10-31

Results of the ARCTIC-INTERRUPTION trial presented at TCT 2013 New study finds patients who are event-free following PCI at 1 year may not need prolonged dual antiplatelet therapy SAN FRANCISCO, CA – October 31, 2013 – According to a new study, patients that do not experience ...

Women under 60 with diabetes at much greater risk for heart disease

2013-10-31

Women under 60 with diabetes at much greater risk for heart disease Results of a Johns Hopkins study published today in the journal Diabetes Care found that young and middle-aged women with type 2 diabetes are at much greater risk of coronary artery disease than ...

Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013

2013-10-31

Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013 Comparison of 2 third-generation drug-eluting stents establishes comparable safety and efficacy; demonstrates non-inferiorityof newest zotarolimus-eluting stent SAN FRANCISCO, CA – October 31, 2013 – Results ...

NASA sees Halloween Typhoon Krosa lashing Luzon, Philippines

2013-10-31

NASA sees Halloween Typhoon Krosa lashing Luzon, Philippines VIDEO: In this flyby animation of Oct. 30, NASA's TRMM satellite found precipitation falling at a rate ...

Pore formation in cell membranes linked to triggers of rheumatoid arthritis

2013-10-31

Pore formation in cell membranes linked to triggers of rheumatoid arthritis Discovery suggests new paths to treatments that stall or reverse protein modifications involved in the autoimmune disease Experiments by scientists at Johns Hopkins and in Boston have unraveled ...

A first step in learning by imitation, baby brains respond to another's actions

2013-10-31

A first step in learning by imitation, baby brains respond to another's actions Imitation may be the sincerest form of flattery for adults, but for babies it's their foremost tool for learning. As renowned people-watchers, babies often observe others demonstrate ...

Incurable brain cancer gene is silenced

2013-10-31

Incurable brain cancer gene is silenced Gene regulation technology increases survival rates in mice with glioblastoma Glioblastoma multiforme (GBM), the brain cancer that killed Sen. Edward Kennedy and kills approximately 13,000 Americans a year, is aggressive ...

Staph infections and eczema: What's the connection?

2013-10-31

Staph infections and eczema: What's the connection? New U-M-led research in animals pinpoints molecule from bacteria that may play key role in prompting skin inflammation &#8211 and could be a target for treatment ANN ARBOR, Mich. — For the millions ...

Listen up: Oysters may use sound to select a home

2013-10-31

Listen up: Oysters may use sound to select a home Oysters begin their lives as tiny drifters, but when they mature they settle on reefs. New research from North Carolina State University shows that the sounds of the reef may attract the young oysters, ...

Silent victims -- an epidemic of childhood exposure

2013-10-31

Silent victims -- an epidemic of childhood exposure Over 15 million children are exposed to intimate partner violence (IPV) each year, and the health consequences of this exposure are well-documented. The Institute of Medicine and the United States ...